October 31, 2016 / 11:51 AM / 3 years ago

BRIEF-Caladrius biosciences begins second cohort of mid-stage trial for treating diabetes

Oct 31 (Reuters) - Caladrius Biosciences Inc -

* Caladrius Biosciences has modified T-rex study protocol to allow for an earlier than planned resumption of enrollment for remaining patients based on DSMB recommendation

* Company now expects to reach milestone of treating 50% of subjects by mid-2017

* Caladrius Biosciences begins enrollment of second cohort of phase 2 trial of clbs03 as a treatment for type 1 diabetes following favorable safety data from first cohort Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below